资产管理业务方面，公司以全资子公司九安香港公司为主，以自有资金从事资产管理业务。截至2025年 半年末，公司多元化配置的资产组合中，固定收益类资产占比59.2%，公开市场权益占比26.2%，私募 股权占比12.6%，对冲基金占比2.0%。 中证报中证网讯(王珞)九安医疗（002432）近日发布的2025年半年度报告显示，上半年公司实现营业收 入7.65亿元；实现净利润9.2亿元，同比增长52.91%。 报告期内，公司的iHealth系列产品以其出色的市场表现和盈利能力，为公司收入和利润做出了重要贡 献。该系列产品的营业收入约6.01亿元人民币，展示了其市场竞争力和盈利能力。公司的试剂盒产品销 量情况良好，特别是在亚马逊平台上，在售价较市场同类产品居前列的同时，销量长期位居该品类的 Best Seller，显示了iHealth产品的市场认可度和品牌价值。 公司在智能助听器领域，拟推出的最新款AI智能助听器尚在研发过程中，该产品搭建全新的移动听力 计算架构，加持AI神经网络助听算法，通过全方位、多层次处理，确保用户可以在任何环境下都能享 受到清晰、自然的听觉体验。目前该项目正在持续稳步推进中，并计划在年内完成样机 ...

资金流向方面，8月15日，九安医疗主力资金净流出10.67万元，近5日总体呈流出状态，5日共流出 1509.03万元。 天津九安医疗电子股份有限公司的主营业务是家用医疗器械的研发、生产及销售。公司的主要产品是 iHealth系列产品、非自主品牌产品、传统硬件产品、互联网医疗产品。 最新一期业绩显示，2025年一季报，公司实现营业收入5.07亿元，同比-33.49%；净利润2.66亿元，同比 7.62%，销售毛利率70.46%。 8月15日，九安医疗今日收盘40.42元，上涨1.58%，滚动市盈率PE（当前股价与前四季度每股收益总和 的比值）达到11.36倍，创92天以来新低，总市值191.70亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均56.58倍，行业中值39.97倍，九安医疗排 名第32位。 序号股票简称PE(TTM)PE(静)市净率总市值(元)1九安医疗11.3611.490.89191.70亿行业平均 56.5852.305.00119.53亿行业中值39.9739.072.9157.03亿2英科医疗15.6416.861.39247.04亿3山东药玻 16.2816.331.871 ...

天津九安医疗电子股份有限公司的主营业务是家用医疗器械的研发、生产及销售。公司的主要产品是 iHealth系列产品、非自主品牌产品、传统硬件产品、互联网医疗产品。 最新一期业绩显示，2025年一季报，公司实现营业收入5.07亿元，同比-33.49%；净利润2.66亿元，同比 7.62%，销售毛利率70.46%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)1九安医疗11.2811.400.89190.28亿行业平均 56.5652.664.92118.97亿行业中值39.7639.192.9457.67亿2英科医疗15.1416.331.35239.25亿3山东药玻 16.1616.211.86152.83亿4振德医疗16.7615.801.0760.86亿5新华医疗17.1715.911.40110.05亿6奥美医疗 17.1816.831.7762.06亿7九强生物17.8916.632.1988.59亿8康德莱18.3218.341.5239.49亿9维力医疗 18.6219.892.3443.64亿10奥泰生物18.7119.731.5159.67亿11鱼跃医疗20.1519.762.7235 ...

Group 1 - The core viewpoint of the news is that Jiuan Medical's stock performance shows a significant decline in its price-to-earnings (PE) ratio, indicating potential undervaluation compared to the industry average [1] - As of August 7, Jiuan Medical's closing price was 39.68 yuan, with a PE ratio of 11.15, which is the lowest in 59 days, and a total market capitalization of 18.819 billion yuan [1] - The average PE ratio for the medical device industry is 54.79, with a median of 37.86, positioning Jiuan Medical at the 32nd rank within the industry [1] Group 2 - On August 7, Jiuan Medical experienced a net inflow of main funds amounting to 59.653 million yuan, although it has seen an overall outflow of 4.2055 million yuan over the past five days [1] - The company's main business includes the research, production, and sales of home medical devices, with key products being the iHealth series, non-self-branded products, traditional hardware products, and internet medical products [1] - In the latest quarterly report for Q1 2025, Jiuan Medical reported a revenue of 507 million yuan, a year-on-year decrease of 33.49%, while net profit was 266 million yuan, reflecting a year-on-year increase of 7.62%, with a gross profit margin of 70.46% [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Jiuan Medical, indicating a significant decline in revenue while maintaining a positive net profit margin [1][2] - Jiuan Medical's stock closed at 38.9 yuan, with a rolling PE ratio of 10.93, which is considerably lower than the industry average of 54.89 [1][2] - The company has a total market capitalization of 18.45 billion yuan, ranking 31st in the medical device industry based on PE ratio [1][2] Group 2 - As of the first quarter of 2025, 11 institutions hold shares in Jiuan Medical, with a total of 2.5028 million shares valued at 0.91 billion yuan [1] - The company's main business includes the research, production, and sales of home medical devices, with key products being the iHealth series and other traditional hardware and internet medical products [1] - In the latest financial report for Q1 2025, Jiuan Medical reported a revenue of 507 million yuan, a year-on-year decrease of 33.49%, while net profit was 266 million yuan, reflecting a year-on-year increase of 7.62% with a gross margin of 70.46% [1]

7月30日，九安医疗今日收盘39.4元，上涨1.18%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到11.07倍，总市值186.87亿元。 从行业市盈率排名来看，公司所处的医疗器械行业市盈率平均55.15倍，行业中值37.48倍，九安医疗排 名第31位。 截至2025年一季报，共有11家机构持仓九安医疗，其中基金11家，合计持股数250.28万股，持股市值 0.91亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入5.07亿元，同比-33.49%；净利润2.66亿元，同比 7.62%，销售毛利率70.46%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)1九安医疗11.0711.200.87186.87亿行业平均 55.1550.114.80115.74亿行业中值37.4836.822.6955.61亿2英科医疗14.0715.171.25222.33亿3新华医疗 15.9114.751.30101.98亿4振德医疗16.1515.221.0358.62亿5山东药玻16.2116.261.86153.29亿6奥美医疗 16.3215.991.6858.96亿7康德莱17.1 ...

Group 1 - The core viewpoint of the news is that Jiuan Medical's stock performance is under pressure, with a significant drop in revenue and a low price-to-earnings (PE) ratio compared to the industry average [1] - Jiuan Medical's closing price on July 16 was 38.6 yuan, down 1.66%, with a rolling PE ratio of 10.85 times and a total market capitalization of 18.307 billion yuan [1] - The company ranks 31st in the medical device industry, which has an average PE ratio of 51.87 times and a median of 37.48 times [1] Group 2 - Jiuan Medical's main business includes the research, production, and sales of home medical devices, with key products being the iHealth series, non-self-branded products, traditional hardware products, and internet medical products [1] - In the latest quarterly report for Q1 2025, Jiuan Medical reported revenue of 507 million yuan, a year-on-year decrease of 33.49%, while net profit was 266 million yuan, an increase of 7.62%, with a gross profit margin of 70.46% [1] - The net outflow of main funds for Jiuan Medical on July 16 was 1.7638 million yuan, with a total outflow of 59.2376 million yuan over the past five days [1]

Company Overview - Jiuan Medical closed at 37.17 yuan, down 1.01%, with a rolling PE ratio of 10.45 times and a total market value of 17.629 billion yuan [1] - The company ranks 32nd in the medical device industry, which has an average PE ratio of 51.10 times and a median of 37.18 times [1] Shareholder Information - As of May 31, 2025, Jiuan Medical had 70,600 shareholders, a decrease of 1,200 from the previous count, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1] Business Operations - Jiuan Medical focuses on the research, production, and sales of home medical devices, with key products including the iHealth series, non-self-branded products, traditional hardware products, and internet medical products [1] Financial Performance - In the first quarter of 2025, Jiuan Medical reported revenue of 507 million yuan, a year-on-year decrease of 33.49%, while net profit was 266 million yuan, an increase of 7.62%, with a gross profit margin of 70.46% [1]

Core Viewpoint - The medical device industry in 2024 faces a complex policy environment and market challenges, with a slight revenue growth of 0.19% but a significant decline in net profit by 13.82%, indicating a divergence in performance across different sub-sectors [1][13]. Medical Equipment - The medical equipment sector experienced a revenue decline of 1.38% and a net profit drop of 17.93% in 2024, with Q1 2025 showing a further revenue decrease of 5.27% and a net profit decline of 14.10% [3][10]. - The decline is attributed to slowed bidding processes and inventory digestion, particularly affecting imaging and monitoring equipment [3][4]. - Leading company, United Imaging Healthcare, reported a revenue of 10.3 billion yuan in 2024, a decrease of 9.73%, marking the first decline in net profit in six years [3][4]. High-Value Consumables - The high-value consumables sector saw a revenue growth of 3.58% but a net profit decline of 4.09% in 2024, with Q1 2025 showing a slight revenue increase of 0.25% and a net profit drop of 6.15% [6][7]. - The sector is impacted by price pressures from national procurement policies, but domestic market share for local brands is improving [6][7]. Low-Value Consumables - The low-value consumables sector achieved a revenue growth of 12.86% and a remarkable net profit increase of 114.83% in 2024, with Q1 2025 showing a revenue growth of 2.37% and a net profit growth of 7.19% [8][9]. - The growth is driven by recovery in the domestic market and accelerated international expansion, particularly in mid-to-high-end markets [8][9]. In Vitro Diagnostics - The in vitro diagnostics sector faced a revenue decline of 6.13% and a net profit drop of 47.04% in 2024, with Q1 2025 showing a further revenue decrease of 15.39% and a net profit decline of 40.27% [10][11]. - The decline is largely due to the high base effect from the COVID-19 pandemic and the impact of various policies, including DRGs and procurement policies [10][11]. Conclusion - The overall revenue growth in the medical device industry is stable, but profit volatility is significant, particularly in the in vitro diagnostics and medical equipment sectors. However, growth drivers remain in low-value consumables' international expansion and innovation, high-value consumables' technological updates, and the gradual recovery of medical equipment [13][14].